Skip to Content

Exact Sciences Corp - Stock Quote EXAS

Rating as of

Morningstar's Exact Sciences Corp Stock Analysis

Valuation
Currency in USD
Is it the right time to buy or sell?
Find out with Morningstar Premium
Is it the right time to buy or sell?
Find out with Morningstar Premium

1-Star Price

PREMIUM

5-Star Price

PREMIUM

Economic Moat

PREMIUM

Capital Allocation

PREMIUM

As Liquid Biopsy Competition Looms, Exact's Growth Stays Strong; Shares Undervalued

Aaron Degagne Equity Analyst

Analyst Note

| Aaron Degagne |

Exact Sciences had a good start to the year, and first-quarter sales of $487 million was slightly above FactSet consensus and in line with our forecasts. We maintain our no-moat, positive moat trend rating, and $76 fair value estimate. After a decline of over 6% on April 26 (seemingly related to broad-based market declines), we now see shares as undervalued, closing at a 23% discount to what we think they are worth.

Read Full Analysis

Exact Sciences Corp's Company Profile

Business Description

Exact Sciences Corporation, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact’s Cologuard screening test, a non-invasive stool-based DNA test, is a pre-cancer screening test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a genetic-based treatment selection test for breast, prostate, and colon cancers. With the acquisitions of Base Genomics and Thrive Earlier Detection, Exact is building a multi-cancer early screening test to detect over 14 cancers, a test that would be one of earliest entrants in multi-cancer liquid biopsy cancer screening.

Contact
5505 Endeavor Lane
Madison, WI, 53719
T +1 608 284-5700
Sector Healthcare
Industry Diagnostics & Research
Most Recent Earnings Mar 31, 2022
Fiscal Year End Dec 31, 2021
Stock Type Speculative Growth
Employees 6,500